Naamidine J

Naamidine J is an imidazole-type alkaloids discovered in a sponge. Naamidine J inhibits inflammation by binding to the protein CSE1L (KD = 5.41 μM) . Namidine J significantly inhibits the expression of pro-inflammatory factors such as TNF-α, IL-1β, and IL-6, and upregulates anti-inflammatory factors such as CD206 and Arg-1. Namidine J inhibits PD-L1 and shows antitumor activity. Namidine J significantly reduces pulmonary tissue edema, inflammatory cell infiltration and cytokine storm in mice. Namidine J can be used for the research on the immune microenvironment of acute lung injury and tumors[1][2].

Product Specifications

CAS Number

[2227550-73-2]

UNSPSC

12352005

Target

Arginase; Interleukin Related; PD-1/PD-L1; TNF Receptor

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease

Field of Research

Cancer; Inflammation/Immunology

Smiles

O=C1N=C(C(N1C)=O)NC2=NC(CC3=CC=C(C=C3)OC)=C(CC4=CC=C(C(OC)=C4)OC)N2C

Molecular Formula

C25H27N5O5

Molecular Weight

477.51

References & Citations

[1]Fu PP, et al. Bioactivity-Driven Synthesis of the Marine Natural Product Naamidine J and Its Derivatives as Potential Tumor Immunological Agents by Inhibiting Programmed Death-Ligand 1. J Med Chem. 2023 Apr 27;66 (8) :5427-5438.|[2]Gao CL, et al. Chemoproteomics of Marine Natural Product Naamidine J Unveils CSE1L as a Therapeutic Target in Acute Lung Injury. J Am Chem Soc. 2024 Oct 16;146 (41) :28384-28397. |[3]Chen E, et al. NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4-acetylated LAMB3-mediated FAK/ERK pathway. Cancer Commun (Lond) . 2025 Sep;45 (9) :1162-1187.